Your Data Needs a Strategy
In the not-so-distant past, physician prescribing data was essentially a…
Success in Rare Disease: Patient Involvement Matters!
This past December, the FDA finalized its guidance on rare diseases with the…
Juggling Geographic Commercialization Priorities
Commercializing a pharmaceutical asset in one country is hard enough. Doing it…
Medical Affairs: An Orchestra, Not a Horse Race
Every horse race has a starting bell, a push to move as fast as possible, and a…
Three Big Mistakes
0 Comments8 Minutes
Over the past 20 years, The NemetzGroup has been involved in the launch of more than 50 different drugs and has had input into the strategic…
The Truth about Teams
0 Comments13 Minutes
When it comes to team performance and adherence to “best practices,” what works on paper or in a teambuilding workshop and what actually occurs are…
Patient Advocacy – Delivering on Patient Centricity in Drug Development
0 Comments9 Minutes
Historically, biopharma companies developed drugs for patients with an illness — but the illness was the primary focus. In recent years, much has…
Beyond the One-Hit Wonder
0 Comments7 Minutes
Survival in Uncertain Times
0 Comments7 Minutes
Like so many seasoned industry professionals, we eagerly seek thought leader perspectives — on the current biopharma industry landscape; the…
Optimize Your Congress Planning
0 Comments8 Minutes
Regardless of your company or drug development stage, congress events are critical undertakings; they represent both a substantial opportunity and a…
Finding Partners: Standing Out in a Field of Many
0 Comments7 Minutes
When biopharma executives or business development leaders think about developing their “partnering story,” the focus is often on the innovation.…
Gaining Participation in Clinical Trials
0 Comments7 Minutes
When it comes to patient recruitment and retention for clinical trials, the bottom line is simply this: It is important and challenging in all…